EXEL Long Put Strategy
EXEL (Exelixis, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F.
EXEL (Exelixis, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $13.77B, a trailing P/E of 16.98, a beta of 0.44 versus the broader market, a 52-week range of 33.76-55.15, average daily share volume of 2.7M, a public-listing history dating back to 2000, approximately 1K full-time employees. These structural characteristics shape how EXEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.44 indicates EXEL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long put on EXEL?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current EXEL snapshot
As of June 30, 2026, spot at $54.48, ATM IV 39.80%, IV rank 45.55%, expected move 11.41%. The long put on EXEL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 52-day expiry.
Why this long put structure on EXEL specifically: EXEL IV at 39.80% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 11.41% (roughly $6.22 on the underlying). The 52-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EXEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on EXEL should anchor to the underlying notional of $54.48 per share and to the trader's directional view on EXEL stock.
EXEL long put setup
The EXEL long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EXEL near $54.48, the first option leg uses a $55.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EXEL chain at a 52-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EXEL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $55.00 | $3.75 |
EXEL long put risk and reward
- Net Premium / Debit
- -$375.00
- Max Profit (per contract)
- $5,124.00
- Max Loss (per contract)
- -$375.00
- Breakeven(s)
- $51.25
- Risk / Reward Ratio
- 13.664
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
EXEL long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on EXEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$5,124.00 |
| $12.05 | -77.9% | +$3,919.53 |
| $24.10 | -55.8% | +$2,715.06 |
| $36.14 | -33.7% | +$1,510.58 |
| $48.19 | -11.5% | +$306.11 |
| $60.23 | +10.6% | -$375.00 |
| $72.28 | +32.7% | -$375.00 |
| $84.32 | +54.8% | -$375.00 |
| $96.37 | +76.9% | -$375.00 |
| $108.41 | +99.0% | -$375.00 |
When traders use long put on EXEL
Long puts on EXEL hedge an existing long EXEL stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying EXEL exposure being hedged.
EXEL thesis for this long put
The market-implied 1-standard-deviation range for EXEL extends from approximately $48.26 on the downside to $60.70 on the upside. A EXEL long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long EXEL position with one put per 100 shares held. Current EXEL IV rank near 45.55% is mid-range against its 1-year distribution, so the IV signal is neutral; the long put thesis on EXEL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, EXEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EXEL-specific events.
EXEL long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EXEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EXEL alongside the broader basket even when EXEL-specific fundamentals are unchanged. Long-premium structures like a long put on EXEL are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current EXEL chain quotes before placing a trade.
Frequently asked questions
- What is a long put on EXEL?
- A long put on EXEL is the long put strategy applied to EXEL (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With EXEL stock trading near $54.48, the strikes shown on this page are snapped to the nearest listed EXEL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are EXEL long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the EXEL long put priced from the end-of-day chain at a 30-day expiry (ATM IV 39.80%), the computed maximum profit is $5,124.00 per contract and the computed maximum loss is -$375.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a EXEL long put?
- The breakeven for the EXEL long put priced on this page is roughly $51.25 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EXEL market-implied 1-standard-deviation expected move is approximately 11.41%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on EXEL?
- Long puts on EXEL hedge an existing long EXEL stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying EXEL exposure being hedged.
- How does current EXEL implied volatility affect this long put?
- EXEL ATM IV is at 39.80% with IV rank near 45.55%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.